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Background: Peripheral artery disease (PAD) is a major complication of atherosclerosis. PAD can be diagnosed with
low-cost diagnostic techniques and is associated with significant morbidity and mortality. While the major epidemiologic
risk factors for PAD have been established in the western world, data from resource-poor countries are limited. We
performed a cross-sectional study to determine the prevalence and correlates of PAD among patients with diabetes
at Mbarara Referral Hospital in southwestern Uganda.
Methods: We consecutively enrolled diabetes patients aged 50 years or greater presenting to the outpatient clinic. We
collected blood for fasting lipid profile, HIV serology, and glycosylated hemoglobin, measured blood pressure and
ankle brachial index, and administered the Edinburgh Claudication Questionnaire (ECQ). We also surveyed patients for
other PAD risk factors. We used logistic regression to determine correlates of PAD.
Results: We enrolled 229 diabetes patients. The median age of 60 years (IQR 55–66), and 146 (63.7%) were female. Fifty
five patients (24%) had PAD (ABI of≤ 0.9). Of these, 48 /55 (87.27%) had mild PAD (ABI 0.71-0.9) while 7/55 (12.73%)
had moderate to severe PAD (ABI < 0.7). Amongst those with PAD, 24/55 (43.64%) reported claudication by the
ECQ. Correlates of PAD included female sex (AOR 2.25, 95% CI 1.06 - 4.77, p = 0.034), current high blood pressure
(AOR 2.59, 95% CI 1.25-5.33, p = 0.01), and being on a sulfonylurea–glibenclamide (AOR 3.47, 95% CI 1.55 - 7.76,
p = 0.002).
Conclusion: PAD was common in diabetic patients in southwestern Uganda. Given its low cost and ease of
measurement, ABI deserves further assessment as a screening tool for both PAD and long term cardiovascular
risk amongst diabetics in this region.Background
Cardiovascular disease is projected to become the lead-
ing cause of death in sub-Saharan Africa within the next
two decades [1]. This epidemiologic shift will have a sig-
nificant impact on health and relative burden of disease in
the region [2]. Epidemiologic data on non-communicable
diseases in this region are lacking and this is in part due to
the non-availability and high cost of diagnostic tools.
Peripheral arterial disease (PAD) is among those non-
communicable diseases that can be diagnosed without
skilled technologists and at low cost by measurement of* Correspondence: okello.samson@must.ac.ug
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unless otherwise stated.the ankle brachial index (ABI). The ABI, therefore, pre-
sents an attractive screening tool for PAD in resource-
poor settings. Studies in resource-rich settings have
shown that ABI is both sensitive and specific as a meas-
ure of lower extremity large vessel atherosclerosis [3-5].
In western countries, PAD patients are at high risk of
myocardial infarction, stroke, amputations, and cardio-
vascular disease related death. Despite this, many pa-
tients with PAD are asymptomatic [6-8]. PAD, therefore,
is an attractive target for screening because its early de-
tection may not only help to delay its progression, but
may also enable improved management of overall car-
diovascular risk [9-14].
While in resource-rich settings, diabetes, smoking, and
old age have been identified as the most important riskLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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rarely diagnosed, in both diabetic and non-diabetic pa-
tients. Consequently, neither is the prevalence of PAD,
nor its risk factors well understood in this region. A bet-
ter understanding of PAD in a population with diabetes
may help guide further research and identify potential
intervention targets. For example, detection of PAD in
such a high risk population may allow for the institution
of relatively simple and low cost medical therapies with
the potential to improve overall cardiovascular risk such
as aspirin, 3-hydroxy-3-methyl-glutaryl-CoA reductase
inhibitors (statins like artovastatin), and angiotensin con-
verting enzyme (ACE) inhibitors [18]. We, therefore, per-
formed a cross-sectional study to determine the prevalence
and correlates of PAD among patients with diabetes at
Mbarara Referral Hospital in Southwestern Uganda. We
hypothesized that diabetic patients in sub-Saharan Africa
would have a prevalence of PAD of 28% (with a 10% preci-
sion) based on what has been found in resource-rich set-
tings (95% CI 19-29%) [19].
Methods
Study design and population
We consecutively enrolled all fasting diabetes patients of
black race, aged ≥ 50 years [20], who presented to the
diabetes outpatient clinic at Mbarara Regional Referral
Hospital in Southwestern Uganda, between January and
June 2012. To be included, patients had to have fasted
on the morning of their clinic appointment. Routinely at
this clinic, all patients are advised to fast on the morning
of their clinic appointment to allow for the measurement
of their fasting blood glucose. We excluded patients with
lower limb amputations and those with suspicion of deep
vein thrombosis (i.e., unilateral leg swelling, constant calf-
muscle pain, and pain on foot flexion) for whom ABI test-
ing would have been inappropriate. All patients gave
written informed consent to participate and ethics ap-
proval was obtained from Mbarara University of Science
and Technology and University of Virginia Institutional
Review Boards. The study was registered with the Uganda
National Council of Science and Technology.
Data collection
Clinical and demographic variables
We surveyed the patients to collect data on smoking his-
tory, hypertension, hyperlipidemia, stroke/transient is-
chemic attack, coronary artery disease, or chronic kidney
disease. We also obtained data on the duration of diabetes
and current medications. We categorized self-reported
smoking as never, former, or current. A physician verbally
administered the Edinburgh Claudication Questionnaire
(ECQ). The ECQ has been shown in English speaking
populations to be 91.3% sensitive and 99.3% specific for
identifying claudication symptoms [21]. To adapt it to thispopulation, the ECQ was pre-tested and translated into
the local language (Runyankole). In addition, we ensured
that it was administered by a physician fluent in the local
language. Given that responses were quantitative, back
translation was not done, and the data was entered dir-
ectly into a database. A composite variable derived from
the responses classified claudication as: none, atypical, or
definite claudication. From the ECQ, definite claudication
was defined as presence of calf pain, regardless of whether
there was pain at other sites. Atypical claudication was de-
fined as having pain in the thigh or buttock in the absence
of calf pain. Finally, no claudication was defined as having
pain in the hamstrings, feet, shins, joints, or any calf, thigh
or buttock pain that appears to radiate, or no pain at all in
any part of the leg [21].
Measurement of ABI
For all patients, we measured the brachial blood pressure
(BP) after a 5-minute rest in the supine position, using an
aneroid sphygmomanometer (Welch Allyn® Tycos DS58
Hand Aneroids; Skaneateles Falls, New York, USA), recali-
brated monthly according to the manufacturers’ manual.
Two BP measurements were taken for each arm with a
third reading performed only if the difference between the
two was greater than 10 mmHg for systolic BP, or greater
than 5 mmHg for diastolic BP. The mean of the closest
two readings was then calculated and taken as the pa-
tient’s BP.
We measured ankle pressures using an aneroid sphygmo-
manometer while using a standardized Doppler ultrasonic
device (8 MHz; Edan™ Sonotrax® MS3-14347A; Shekou,
China) to accentuate the sounds over the posterior tibial
and dorsalis pedis arteries. The ankle–brachial index for
each leg was calculated by dividing the higher of two sys-
tolic BP readings at the ankle (i.e., one from the dorsalis
pedis and the other from the posterior tibial artery) by the
higher of the two brachial systolic BP readings from the
ipsilateral arm (i.e., from the brachial artery). For all pa-
tients, measurements on both legs were obtained, and the
lower value was considered as the patient’s ABI [20,22,23].
Laboratory-based measurements
We measured fasting blood glucose level and glycosyl-
ated hemoglobin (HbA1c) levels using a hand-held gluc-
ometer (Abbott Optium Xceed® Diabetes Monitoring
System; Abbott laboratories™, Illinois, USA) and a standard
HbA1c rapid test kit (A1CNow + ®; Bayer™ HealthCare,
Sunnyvale, CA, USA) respectively. We also tested patients
for HIV serology using a standard algorithm and standard
rapid testing kits, with a sensitive initial screen (Alere™
HIV-1/2 Determine® dipstick) followed by a more specific
confirmatory test(STAT-PAK® HIV-1/2), with only the in-
conclusive results being subjected to a third rapid test as a
tie breaker (Uni-Gold™ Recombigen® HIV). In addition, we
Table 1 Characteristics of the study population
Characteristic N = 229
Age (years), median (IQR) 60 (55–66)
Female sex, n (%) 146 (63.7)
Current smoker, n (%) 12 (5.2)
Former smoker, n (%) 82 (35.8)
Never smoked 135 (59)
Duration of diabetes (years), median (IQR) 1.0 (0.3–2.3)
Family history of diabetes, n (%) 78 (34.1)
No Claudication, n (%) 126 (55.0)
Atypical Claudication, n (%) 54 (23.6)
Definite Claudication, n (%) 49 (21.4)
Self-reported hypertension, n (%) 113 (49.3)
HIV infection, n (%) 18 (7.9)
Diabetes treatmentπ, n (%)
Metformin only 112 (51.6)
Glibenclamide only 2 (0.9)
Glibenclamide and Metformin 34 (15.7)
Insulin only 52 (24)
Insulin and Metformin 15 (6.9)
Aspirin, n (%) 17 (7.4)
BMI (kg/m2), median (IQR) 26.3 (22.6–29.4)
Waist-to-hip ratio, median (IQR) 1 (1–1)
Systolic blood pressure (mmHg), median (IQR) 140 (124–160)
Diastolic blood pressure (mmHg), median (IQR) 80 (70–90)
Fasting blood sugar (mmol/L), median (IQR) 8.6 (6.6–13.7)
HbA1c (%), median (IQR) 8.1 (6.7–10.1)
HDL£-Cholesterol (mg/dL), median (IQR) 48 (39–58)
LDL¥-Cholesterol (mg/dL), median (IQR) 81 (63–96)
Triglycerides (mg/dL), median (IQR) 116 (83–179)
Total cholesterol (mg/dL), median (IQR) 268 (212–307)
IQR: Inter quartile range; HIV: Human immunodeficiency virus; BMI: body mass
index; HDL£: High-density Lipoprotein- cholesterol; LDL¥: Low-density
lipoprotein-cholesterol; HbA1c: glycated hemoglobin.
Diabetes treatmentπ: A total of 217 patients were on diabetes medication.
Okello et al. BMC Cardiovascular Disorders 2014, 14:75 Page 3 of 6
http://www.biomedcentral.com/1471-2261/14/75obtained serum total cholesterol (TC), triglyceride (TG),
high-density lipoprotein cholesterol (HDL-C), and low-
density lipoprotein cholesterol (LDL-C) levels, using an
automated clinical chemistry analyzer (Humastar® 180;
Human Diagnostics Worldwide, Wiesbaden, Germany). The
tests were performed at the Mbarara University Clinical
Research Laboratory which participates in external quality
assurance programs by the National Health Laboratory
Service (Johannesburg, South Africa).
Study definitions
We defined diabetes as a fasting glucose level ≥ 7.0 mmol/L
(127 mg/dL), or taking medication for diabetes, or having
been diagnosed with diabetes by a physician. We defined
poor glycemic control as HbA1c > 7.0% (> 53 mmol/mol)
[24]. Hypertension was defined as a systolic blood pres-
sure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg
or having been on hypertensive medications. Obesity
was defined as a BMI ≥ 30 kg/m2, or a waist-to-hip
ratio ≥ 0.81 or ≥ 0.96 for females and males respect-
ively [25]. We defined hypercholesterolemia, high LDL-
cholesterol, low HDL-cholesterol, hypertriglyceridemia,
respectively, as serum cholesterol levels greater than
190 mg/L (4.9 mmol/L), LDL-cholesterol greater than
100 mg/dL (2.50 mmol/L), HDL-cholesterol levels less
than 40 mg/L (1.03 mmol/L), and serum triglyceride levels
greater than 200 mg/L (2.26 mmol/L) respectively [26].
We defined mild PAD as an ABI ≥ 0.71 but ≤ 0.90, moder-
ate PAD as an ABI ≥ 0.40 but ≤ 0.70, and severe PAD as an
ABI < 0.40 [20]. We considered a patient with PAD as be-
ing on PAD-appropriate medical therapy if they reported
taking either aspirin or clopidigrel. However, for those
with hypertension required an additional drug in form of
a statin, or an ACEI to be considered as being on PAD ap-
propriate therapy.
Statistical methods
We summarized demographic and clinical characteristics,
reporting proportions for categorical and binary variables,
and median and interquartile range for continuous vari-
ables. We further divided the cohort into those with and
without PAD and fit logistic regression models to deter-
mine the correlates PAD. In the multivariable models,
we adjusted for sex, current high blood pressure, and
taking glibenclamide). Statistical significance was set
at p ≤ 0.05. We performed all statistical analyses using
Stata 12 (StataCorp, College Station, Texas, USA).
Results
Of 256 patients who were screened, 27 did not meet in-
clusion criteria and were excluded. Thirteen were aged ≤
49 years, eight had no diabetes, one had an above-knee
amputation, five declined participation, two withdrew
consent, and one did not complete study procedures.Summary demographic and clinical characteristics for
the remaining 229 patients are shown in Table 1. The co-
hort had a median age of 60 years, had been known to
be diabetic for a median of 1.0 year (IQR 0.3-2.3), and
had a median HbA1c of 8.1% (6.7-10.1). Twenty-nine per-
cent were taking insulin, and 41% were former or current
smokers.
The prevalence of PAD (ABI of ≤ 0.9) was 24% (55/229).
Among the patients with PAD, 48/55 (87%) had mild PAD
(ABI 0.71-0.90) while 7/55 (13%) had moderate to severe
PAD (ABI < 0.70). Based on the ECQ, 31/55 (56%) of those
with PAD were asymptomatic, whereas only 11/55 (20%)
showed definite claudication, and 13/55 (24%) had atypical
Table 3 Multivariable adjusted predictors of Peripheral
Artery Disease
Characteristic AOR 95% CI p-value
Glibenclamide use 3.47 1.55 - 7.76 0.002
Current high blood pressureβ 2.59 1.25 - 5.33 0.01
Female sex 2.25 1.06 - 4.77 0.034
Current high blood pressure β: clinic measured systolic blood pressure ≥ 140 mmHg
and/or diastolic blood pressure ≥ 90 mmHg; AOR: Adjusted odds ratio.
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PAD, 6/55 (11%) were taking aspirin, and only 1 patient
was taking a statin. Thirty three of 113 (29.2%) patients
who had hypertension with concurrent PAD were on an
ACE inhibitor or ARB.
In the unadjusted analysis (Table 2), female sex, self-
reported hypertension, current high blood pressure, and
duration of diabetes were associated with PAD. In the
multivariable adjusted analysis, (Table 3), female sex
(AOR 2.25, 95% CI 1.06–4.77, p = 0.034), current high
blood pressure (AOR 2.59, 95% CI 1.25–5.33, p = 0.01),
and being on sulfonylurea–glibenclamide (AOR 3.47,
95% CI 1.55–7.76, p = 0.002) were independently associ-
ated with PAD.
Discussion
To the best of our knowledge, this is the first report of
the prevalence of PAD in patients with diabetes in Sub-
Sahara Africa. The prevalence of PAD of 24%, as found
in our study based on ABI, was substantially higher than
previous estimates (0.2–3.4%) which were based on clin-
ical parameters such as weak or absent peripheral pulses,
or development of dry gangrene [27,28]. However, ourTable 2 Unadjusted analysis of predictors of Peripheral
Artery Disease
Characteristic OR (95% CI) p-value
Female sex 2.47 (1.22–5.01) 0.0001
Smoking history 1.04 (0.56–1.93) 0.894
Duration of diabetes > 5 years 3.38 (0.94–12.15) 0.062
Family history of diabetes 1.37 (0.73–2.56) 0.326
Presence of claudication symptoms 0.93 (0.51–1.71) 0.819
Self-reported hypertension¥ 1.96 (0.95–3.26) 0.072
Current elevated blood pressureβ 2.73 (1.42–5.25) 0.003
HIV infection 0.61 (0.17–2.19) 0.451
Metformin use 0.74 (0.39–1.42) 0.367
Glibenclamide use 3.16 (1.50–6.66) 0.002
Insulin use 1.24 (0.65–2.38) 0.517
Obesity, BMI≥ 30 Kg/m2 1.23 (0.59–2.53) 0.576
Waist-to-hip ratio≥ 0.81 (F) or ≥ 0.96 (M) 0.83 (0.21–3.26) 0.796
Cholesterol ≥ 190 mg/dL 0.9 (0.41–1.98) 0.794
HDL€≤ 40 mg/dL 1.21 (0.61–2.41) 0.581
LDLα≥ 100 mg/dL 1.39 (0.69–2.78) 0.355
TG∞≥ 200 mg/dL 0.75 (0.34–1.67) 0.483
FBSμ < 3.9 or > 7.2 mmol/L 0.87 (0.46–1.65) 0.679
HbA1c£ > 7.0% (53 mmol/mol) 0.75 (0.39 - 1.41) 0.368
Self-reported hypertension¥: prior diagnosis of hypertension and taking
antihypertensive drugs; Current elevated blood pressureβ: clinic systolic blood
pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg; OR: Odds
ratio; BMI: body mass index; HDL€: High-density Lipoprotein- cholesterol; LDLα:
Low-density lipoprotein-cholesterol; TG∞: Triglycerides; FBSμ: fasting blood
sugar; HbA1c£: glycated hemoglobin.finding is comparable to the upper end of the range
(1.7–28%) found when ABI was measured by echo-
graphic and doppler flow velocity waveform analysis
methods [2]. The prevalence of PAD in our study popula-
tion is also well within the range of several screening stud-
ies in the US that used a similar screening technique, and,
in African American diabetic patients, found a prevalence
of PAD between 14-30% [29-31]. The low proportion of
smokers in our study (5.2%) reflects the low national
smoking prevalence in Uganda [32].
In the multivariable-adjusted analysis, we found that
female sex, current high blood pressure, and use of glib-
enclamide were predictive of PAD. Population based
studies have previously reported an association of PAD
with female sex [33] and hypertension [34], which we
have also shown in our study. In our clinic, the majority
of the patients are of the female sex [35]. This pattern
may be because females generally outnumber males in
the Ugandan population and, in addition, they tend to
have better health seeking behaviour [36,37]. We were
unable to assess independent association of smoking
with PAD because of a very low prevalence of smoking.
A low prevalence of smoking has been reported in the
general Ugandan population, and the prevalence is even
lower in females [32,35,37]. It is therefore possible that
the observed lack of association with smoking with PAD
may be due to the high female proportion in the setting
of a low prevalence of smoking in females. Given this
observation, the finding that female sex was an inde-
pendent predictor of PAD may or may not represent a
real association in this population, and, therefore, de-
serves further investigation in future studies.
Despite international recommendations for use of as-
pirin, ACEIs, and statins for PAD [18], our study shows
that diabetes patients are undertreated with regard to
atherosclerotic risk factor modification. This may be be-
cause patients with diabetes can be asymptomatic even
in the presence of serious cardiovascular complications.
PAD screening in these patients may therefore enhance
the awareness of active cardiovascular complications and
allow for more risk factor treatment. We do appreciate
that there can be a high rate of noncompliance to medi-
cation for chronic non-communicable disease is in our
setting. However, our finding of a high prevalence of
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existence of prevention opportunities in this population.
Although sulfonylureas, including glyburide and glicla-
zide, have been associated with an increased mortality
from acute coronary syndrome in type 2 diabetes patients
[38], we know of no prior study that has reported an asso-
ciation between glibenclamide use and PAD. This may,
therefore, be a spurious finding from our study. However,
the association was independent of concurrent metformin
use, diabetes duration and severity (as assessed through
HbA1c). In addition, those taking insulin were not at
increased risk of PAD, indicating the increased risk of
PAD in those on glibenclamide may not be related to the
known risk of hypoglycemia that occurs with glibencla-
mide. Thus, our findings may suggest an independent as-
sociation between PAD and glibenclamide use (Table 3)
requiring further investigation.
Previous studies have reported that even among pa-
tients with a low ABI and thus confirmed PAD, absence
of “leg” symptoms is not very useful in excluding PAD
[6,20]. We found that only 20% of those with PAD had
definite claudication, and that over half had no claudica-
tion symptoms on the ECQ. This is similar to what has
been found by studies in resource rich settings where
this tool showed 20% sensitivity in diagnosing PAD [16].
Our data similarly suggest that claudication symptoms
are not very helpful in excluding PAD in Sub-Saharan
Africa.
The findings in this report are subject to a number of
limitations. First, this was a cross sectional study in a
population with diabetes where the risk for PAD is high.
Second, the patients studied were from a referral center.
These observations imply that our findings may not neces-
sarily represent the general Ugandan population, or those
patients presenting in primary care settings. In addition,
our findings may not reflect the prevalence of PAD if it
was measured using other screening criteria. However, our
data suggest that criteria applied in resource-rich settings
may as well be applicable in the resource-poor setting.
Conclusion
In conclusion, PAD was common among diabetes outpa-
tients ≥ 50 years old presenting at a referral hospital in
southwestern Uganda. Given that this is a group at high
risk of cardiovascular complications, the high prevalence
of PAD in a setting of under-treatment of general car-
diovascular risk, call for further study of PAD in this
population. For example, future studies could investigate
whether screening for PAD in this population using
ABIs might lead to increased use of evidence-based
treatments that are known to reduce general cardiovas-
cular risk. Future research should also attempt to deter-
mine the prevalence and risk factors of PAD in more
generalized populations in sub-Saharan Africa.Abbreviations
ABI: Ankle-Brachial Index, PAD, Peripheral Artery Disease, AOR, Adjusted Odds
Ratio.
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